This research project investigates the risk factors for heart damage (cardiotoxicity) caused by doxorubicin, a common chemotherapy drug used to treat dogs with multicentric B-cell lymphoma. While effective, doxorubicin can harm the heart, particularly after multiple doses. The study aims to validate a method for measuring doxorubicin levels in dogs' blood and to understand how factors like breed, weight, and liver function influence drug concentration and heart effects. By analyzing these factors, the project seeks to improve treatment safety through personalized dosing strategies, ultimately enhancing outcomes for canine cancer patients.

• dr. M.M.J.M. (Maurice) Zandvliet
• dr. G. (Giorgia) Santarelli
• prof. dr. Ronette Gehring